Paion "buy" (Seite 3896)
eröffnet am 12.07.05 19:39:23 von
neuester Beitrag 12.04.24 13:32:35 von
neuester Beitrag 12.04.24 13:32:35 von
Beiträge: 123.397
ID: 992.863
ID: 992.863
Aufrufe heute: 67
Gesamt: 16.514.455
Gesamt: 16.514.455
Aktive User: 0
ISIN: DE000A3E5EG5 · WKN: A3E5EG · Symbol: PA8
0,0282
EUR
-17,06 %
-0,0058 EUR
Letzter Kurs 16:42:21 Tradegate
Neuigkeiten
22.12.23 · 4investors |
22.12.23 · wO Newsflash |
22.12.23 · EQS Group AG |
24.11.23 · 4investors |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9000 | +59,66 | |
| 4,7450 | +35,57 | |
| 2,2999 | +25,68 | |
| 1,9200 | +23,87 | |
| 6,9300 | +17,46 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 6,9800 | -12,31 | |
| 0,5050 | -15,83 | |
| 3,1100 | -18,10 | |
| 1,9500 | -25,14 | |
| 0,5121 | -30,80 |
Beitrag zu dieser Diskussion schreiben
Feedback
nur noch mal der Hinweis das war nur ein Auszug unten recht kann man das ganze dann weiter blättern ......
Zitat aus : " https://seekingalpha.com/article/4284497-paion-ag-paiof-ceo-…
PAION AG (PAIOF) CEO Wolfgang Söhngen on Q2 2019 - Earnings Call Transcript
Aug. 11, 2019 5:52 AM ET | About: Paion AG (PAIOF)
PAION AG (OTC:PAIOF) Q2 2019 Results Earnings Conference Call August 6, 2019 8:00 AM ET
Company Participants
Ralf Penner - VP, IR
Wolfgang Söhngen - CEO
Abdelghani Omari - CFO
Conference Call Participants
Simon Scholes - First Berlin
Christian Ehmann - FMR Research
Ralf Penner
Thank you very much for your kind introduction. Dear, ladies and gentlemen, thank you very much for joining us for PAION's Earnings Call on the Financial Results of the First Half of 2019. My name is Ralf Penner. I'm PAION's Vice President, Investor Relations, and I'll be moderating today's call.
I'm joined by Wolfgang Söhngen, PAION's CEO; as well as Abdelghani Omari, our Chief Financial Officer. Within the next half hour, we are going to highlight some of the page 129 in achievements, give details on the financial results, highlight the most important events and provide the pipeline and strategy update and financial outlook. After this initial presentation, we will be happy to take questions.
I would like to point out that the slides for the presentation can be accessed by webcast in parallel to this conference call. The webcast details has been posted on our website and were also given in today's press release. If you have not already opened webcast link, you may want to do so now. This conference call is being recorded and then audio recording will be available later today and will be posted on our website.
Before we get started, I would like to remind you that today's call may include forward-looking statements and that actual results may vary from PAION's current anticipations. I would also like to refer to the disclaimer included in the presentation slides. [Foreign Language] After these initial remarks, I believe that we shall start right on now with the presentation.
Wolfgang, please go ahead.
Wolfgang Söhngen
Thank you very much, Ralf. I would like to start actually with stating that the first half year was very successful for PAION. We now have made significant progress compared to same time of last year. Three filings are underway. We even have a PDUFA date for April, 2020 for the U.S. and our partners are making good progress and we also make good progress with the partner we have to contribute.
For those who are not familiar with the company, I would like to start with the brief overview. We have specialty pharma with a focus on anesthesia product, we want to expand into acute and critical care in the future, where we mentioned it’s in final stage of development with three filings but we still have one indication that we need to redevelop.
We already have eight recent partnerships ranging from the U.S. over China, South Korea, Canada, Russia, Turkey, MENA region and Japan. We have slightly increased our in-house manpower in order to manage also the future plans of supply and entering the market in Europe.
We had 19 million cash at the end of the half year and our market kept fluctuating on 150 million. Right now, in the supervisory board, we had a change with since the last AGM, John Dawson, thank from this end for his contribution over the year’s and has been followed by Dr. Markus Leyck Dieken, who is now having a position in the Gematik in Germany dealing with Artificial Intelligence and Healthcare.
Our management team consists of Dr. Irina, who will talk after me. Jürgen Beck, who is the Chief Development Officer and myself, and we are listed on the Frankfurt Stock Exchange since 2005. Market cap as I said fluctuating 150 million, liquidity described okay for Germany listed biotech company and we have 64 million shares outstanding and we have good support by our analysts.
And remimazolam our one and only product has potentially three different indications. The lead indication historically is different between the regions and general anesthesia was the lead indication in Japan and is the lead -- and used to be the lead indication in Europe, procedural sedation the lead indication for the U.S. and ICU sedation we have completed a Phase II study in Japan and there’s just the indication that we want to takeover in the near future.
PAION AG (PAIOF) CEO Wolfgang Söhngen on Q2 2019 - Earnings Call Transcript
Aug. 11, 2019 5:52 AM ET | About: Paion AG (PAIOF)
PAION AG (OTC:PAIOF) Q2 2019 Results Earnings Conference Call August 6, 2019 8:00 AM ET
Company Participants
Ralf Penner - VP, IR
Wolfgang Söhngen - CEO
Abdelghani Omari - CFO
Conference Call Participants
Simon Scholes - First Berlin
Christian Ehmann - FMR Research
Ralf Penner
Thank you very much for your kind introduction. Dear, ladies and gentlemen, thank you very much for joining us for PAION's Earnings Call on the Financial Results of the First Half of 2019. My name is Ralf Penner. I'm PAION's Vice President, Investor Relations, and I'll be moderating today's call.
I'm joined by Wolfgang Söhngen, PAION's CEO; as well as Abdelghani Omari, our Chief Financial Officer. Within the next half hour, we are going to highlight some of the page 129 in achievements, give details on the financial results, highlight the most important events and provide the pipeline and strategy update and financial outlook. After this initial presentation, we will be happy to take questions.
I would like to point out that the slides for the presentation can be accessed by webcast in parallel to this conference call. The webcast details has been posted on our website and were also given in today's press release. If you have not already opened webcast link, you may want to do so now. This conference call is being recorded and then audio recording will be available later today and will be posted on our website.
Before we get started, I would like to remind you that today's call may include forward-looking statements and that actual results may vary from PAION's current anticipations. I would also like to refer to the disclaimer included in the presentation slides. [Foreign Language] After these initial remarks, I believe that we shall start right on now with the presentation.
Wolfgang, please go ahead.
Wolfgang Söhngen
Thank you very much, Ralf. I would like to start actually with stating that the first half year was very successful for PAION. We now have made significant progress compared to same time of last year. Three filings are underway. We even have a PDUFA date for April, 2020 for the U.S. and our partners are making good progress and we also make good progress with the partner we have to contribute.
For those who are not familiar with the company, I would like to start with the brief overview. We have specialty pharma with a focus on anesthesia product, we want to expand into acute and critical care in the future, where we mentioned it’s in final stage of development with three filings but we still have one indication that we need to redevelop.
We already have eight recent partnerships ranging from the U.S. over China, South Korea, Canada, Russia, Turkey, MENA region and Japan. We have slightly increased our in-house manpower in order to manage also the future plans of supply and entering the market in Europe.
We had 19 million cash at the end of the half year and our market kept fluctuating on 150 million. Right now, in the supervisory board, we had a change with since the last AGM, John Dawson, thank from this end for his contribution over the year’s and has been followed by Dr. Markus Leyck Dieken, who is now having a position in the Gematik in Germany dealing with Artificial Intelligence and Healthcare.
Our management team consists of Dr. Irina, who will talk after me. Jürgen Beck, who is the Chief Development Officer and myself, and we are listed on the Frankfurt Stock Exchange since 2005. Market cap as I said fluctuating 150 million, liquidity described okay for Germany listed biotech company and we have 64 million shares outstanding and we have good support by our analysts.
And remimazolam our one and only product has potentially three different indications. The lead indication historically is different between the regions and general anesthesia was the lead indication in Japan and is the lead -- and used to be the lead indication in Europe, procedural sedation the lead indication for the U.S. and ICU sedation we have completed a Phase II study in Japan and there’s just the indication that we want to takeover in the near future.
Antwort auf Beitrag Nr.: 61.225.467 von submersus am 11.08.19 14:59:45
J
Das ist doch der Hammer was ein Handy aus ein Diktat macht sorry meint natürlich Hana ....
Antwort auf Beitrag Nr.: 61.225.179 von XXMI am 11.08.19 13:39:27 Ich sage dir wir machen es genau richtig wir sind von dem Produkt überzeugt wollen Profit machen und machen jetzt schon Werbung dafür ich hoffe Paion Verhandelt weiter über restliche Gebiete in Süd Ost Asien sollte langsam aber mal was kommen
Antwort auf Beitrag Nr.: 61.224.569 von submersus am 11.08.19 10:17:20🤔
Aus Asienhttp://www.hanaph.co.kr/eng/company/companyDetail.do?num=94 wird vermutlich die nächste News kommen.
Hana ist geradezu berauscht von Remi😊
Aus Asienhttp://www.hanaph.co.kr/eng/company/companyDetail.do?num=94 wird vermutlich die nächste News kommen.
Hana ist geradezu berauscht von Remi😊
Trading Spotlight
in dieser Woche am 16,08 feiert Remi in China seinen 09.monatigen Geburtstag........
Antwort auf Beitrag Nr.: 61.224.308 von Popeye82 am 11.08.19 09:11:12peinliche Nummer, schreib was von Interesse schreib was über paion .........
Antwort auf Beitrag Nr.: 61.224.053 von submersus am 11.08.19 07:50:42Dankeschön für Ihre Meinung.
!
Dieser Beitrag wurde von FairMOD moderiert. Grund: Persönliche Differenzen bitte via BM klären, themenfremd
Antwort auf Beitrag Nr.: 61.214.465 von walle1fc am 09.08.19 12:09:23 Diese hü oder hott bzw. heute alles Sonnenschein morgen wieder Gewitter Forumsteilnehmer nerven einfach.
______________________________________________________________________________
ja, kenne ich.
______________________________________________________________________________
ja, kenne ich.
Durchsuchen
Paion "buy"
